CLDN18 and neoplasm: In total, 13.1% (n = 21) of the enrolled patients showed moderate‐to‐strong membranous staining of VENTANA® CLDN18 antibody in more than 75% (75–100%, median = 90%) of the tumour cells while 86.9% (n = 139) were negative (Supporting information, Figure S1).